,fei_number,recalling_firm_name,product_type,product_classification,status,distribution_pattern,recalling_firm_city,recalling_firm_state,recalling_firm_country,center_classification_date,reason_for_recall,product_description,event_id,event_classification,product_id,center,recall_details
122,2416101.0,Pfizer Inc.,Drugs,Class III,Ongoing,Nationwide in the USA,New York,New York,United States,2023-04-13,"Labeling: Incorrect or Missing Lot and/or Exp Date: 
The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.","MEKTOVI (binimetinib) tablets, 15 mg, 180-count bottle, Rx only, Distributed by: Array BioPharma Inc., a wholly owned subsidiary of Pfizer Inc., Boulder, CO 80301.  NDC:  70255-010-02",91872,Class III,199084,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=199084
1426,2416101.0,Pfizer Inc.,Drugs,Class I,Ongoing,USA nationwide and Puerto Rico,New York,New York,United States,2023-01-25,Presence of Particulate Matter: Glass particulate matter detected in injectable.,"Vancomycin Hydrochloride for Injection, USP, 1.5 g/vial, Sterile powder, Single-dose Fliptop Vial,  10 vials per carton, Rx only, Distributed by: Hospira, Inc., Lake Forest, IL 60045.  NDC Vial 0409-3515-11; NDC Carton 0409-3515-01",91346,Class I,197526,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=197526
1780,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide in the USA.,New York,New York,United States,2023-01-05,Lack of assurance of sterility: Bags have the potential to leak.,"Heparin Sodium 2,000, USP Units, per 1,000 mL (2 USP Units/mL) in 0.9% Sodium Chloride Injection, 1,000 mL bags, a) Case (NDC 0409-7620-59), b) Single Unit (NDC 0409-7620-49), Rx only, Distributed By Hospira, Inc., Lake Forest, IL 60045 USA,",91379,Class II,197588,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=197588
3101,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Distributed in the United States and Puerto Rico.,New York,New York,United States,2022-10-04,Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.,"Aminophylline Injection, USP 250 mg/10 mL (25 mg/mL) 25x10 mL Single-dose vial, Rx only,  Distributed by Hospira, Inc. Lake Forest, IL 60045 USA. NDC 0409-5921-16 (vial) 0409-5921-01 (carton)",90903,Class II,196174,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=196174
3287,2416101.0,Pfizer Inc.,Drugs,Class I,Ongoing,USA Nationwide,New York,New York,United States,2022-09-19,Presence of particulate matter,"PROPOFOL Injectable Emulsion, 1 g/100 mL (10 mg/mL), packaged in 100 mL glass fliptop vial (NDC 0409-4699-54) further packaged in a tray of 10 vials (NDC Carton: 0409-4699-24), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA",90785,Class I,195719,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=195719
4012,2416101.0,Pfizer Inc.,Drugs,Class I,Ongoing,USA Nationwide,New York,New York,United States,2022-08-03,Presence of particulate matter: particulate identified as a beetle.,"Propofol Injectable Emulsion, 1 g/100 mL (10 mg/mL), packaged in 100 mL per glass fliptop vial (NDC 0409-4699-54) further packaged in a tray of 10 vials (NDC Carton: 0409-4699-24), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA",90581,Class I,194853,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=194853
5440,2416101.0,Pfizer Inc.,Drugs,Class II,Completed,Nationwide and Puerto Rico,New York,New York,United States,2022-05-16,CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.,"Accupril (Quinapril HCl Tablets) 10 mg,  90 Tablets Rx only NDC 0071-0530-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017",90064,Class II,193267,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=193267
5441,2416101.0,Pfizer Inc.,Drugs,Class II,Completed,Nationwide and Puerto Rico,New York,New York,United States,2022-05-16,CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.,"Accupril (Quinapril HCl Tablets) 20 mg,  90 Tablets, Rx only NDC 0071-0532-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017",90064,Class II,193268,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=193268
5442,2416101.0,Pfizer Inc.,Drugs,Class II,Completed,Nationwide and Puerto Rico,New York,New York,United States,2022-05-16,CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.,"Accupril (Quinapril HCl Tablets) 40 mg,  90 Tablets, Rx only NDC 0071-0535-23 Distributed by: Parke-Davis Division of Pfizer Inc. NY, NY 10017",90064,Class II,193269,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=193269
5933,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"Accuretic (quinapril HCl/hydrochlorothiazide) Tablets, 10 mg/12.5 mg*, 90 Tablets bottles, Rx Only, Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017, Made in Germany,  NDC 0071-3112-23.
",89864,Class II,192709,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192709
5934,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"Accuretic (quinapril HCl/hydrochlorothiazide) Tablets 10 mg/12.5 mg 90 tablets bottle, Rx Only, Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017, Made in Germany, NDC 0071-0222-23

",89864,Class II,192829,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192829
5935,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"Accuretic (quinapril HCl/hydrochlorothiazide) Tablets, 20 mg/12.5 mg, 90 tablets bottles, Rx Only Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017, Made in Germany, NDC 0071-0220-23.


",89864,Class II,192830,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192830
5936,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"Accuretic (quinapril HCl/hydrochlorothiazide) Tablets, 20 mg/25 mg, 90 tablets bottles, Rx Only, Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017, Made in Germany,  NDC 0071-0223-23.



",89864,Class II,192831,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192831
5937,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"quinapril and hydrochlorothiazide tablets, 20 mg/25 mg*, 90 Tablets bottles, Rx Only, Distributed by: Greenstone, LLC, Peapack, NJ, 07977, Made in Germany,  NDC 59762-5225-9

",89864,Class II,192837,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192837
5938,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"quinapril HCl/hydrochlorothiazide tablets, 20 mg/12.5 mg*, 90 Tablets bottles, Rx Only, Distributed by: Greenstone, LLC, Peapack, NJ, 07977, Made in Germany,  NDC 59762-0220-1

",89864,Class II,192887,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192887
5939,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"quinapril HCl/hydrochlorothiazide tablets, 20 mg/25 mg*, 90 Tablets, Rx Only, Distributed by: Greenstone, LLC, Peapack, NJ, 07977, Made in Germany,  NDC 59762-0223-1

",89864,Class II,192888,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192888
5940,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2022-04-06,CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.,"Accuretic (quinapril HCl/hydrochlorothiazide) tablets, 20 mg/12.5 mg*, 90 Tablets, Rx Only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY. NY 10017, Made in Germany,  NDC 0071-5212-23

.",89864,Class II,192889,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=192889
8036,2416101.0,Pfizer Inc.,Drugs,Class II,Completed,USA Nationwide,New York,New York,United States,2021-12-02,Lack of sterility assurance: bag has the potential to leak.,"5% Dextrose Injection, USP, 50 mL ADD-Vantage Unit, Rx only, Distributed by Hospira, INC., Lake Forest, IL 60045 USA, NDC 0409-7100-68/0409-7100-66",89100,Class II,190482,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=190482
9259,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-09-17,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit,"Chantix (varenicline) tablets 0.5mg/1mg, 56 Tablets, Rx only,  Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 00069-0471-03.
carton containing one blister pack of 11 0.5 mg tablets and one blister pack containing 42.1 mg tablets.",88497,Class II,188806,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=188806
9260,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-09-17,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit,"Chantix (varenicline) tablets 0.5mg, 56 Tablets, Rx only,  Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 0069-0468-56.
",88497,Class II,189285,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=189285
9261,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-09-17,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit,"Chantix (varenicline) tablets 1 mg, 56 Tablets, Rx only,  Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 0069-0469-56.
",88497,Class II,189286,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=189286
9262,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-09-17,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit,"Chantix (varenicline) tablets 1 mg, Carton containing 4 blister packs of 14 tablets each,, Rx only,  Distributed by Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Ireland, NDC 0069-0469-03.
EXPIRATION DATE: September 2021   June 2023
",88497,Class II,189288,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=189288
9954,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-07-30,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit,"Chantix (varenicline) tablets, 0.5mg*, 56 Tablets, Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc., NY, NY 10017, Made in Ireland.
NDC 0069-0468-56	",88077,Class II,187826,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=187826
9955,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-07-30,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit,"Chantix (varenicline)Tablets, Contains: 1 Starting Week (0.5 mg* x 11 tablets), 3 Continuing Weeks (1 mg x 42 tablets), Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, Made in Ireland,
NDC 0069-0471-03.",88077,Class II,187911,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=187911
9956,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide,New York,New York,United States,2021-07-30,CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit,"Chantix (varenicline) tablets, 1 mg, 56 Tablets, Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc., NY, NY 10017, Made in Ireland.
NDC 0069-0469-56	",88077,Class II,188225,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=188225
10598,3012988044.0,"PFIZER, INC",Drugs,Class I,Terminated,"Nationwide in the USA, Puerto Rico, and Guam",Lake Forest,Illinois,United States,2021-06-10,"Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP","0.5% Bupivacaine Hydrochloride Injection, USP, 150 mg/30 mL (5 mg/mL), 30 mL Single-dose Teartop Vials (NDC 0409-1162-19), packaged in 25 vials per tray (NDC 0409-1162-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.",87837,Class I,187220,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=187220
10599,3012988044.0,"PFIZER, INC",Drugs,Class I,Terminated,"Nationwide in the USA, Puerto Rico, and Guam",Lake Forest,Illinois,United States,2021-06-10,"Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP","1% Lidocaine HCl Injection, USP, 300 mg/30 mL (10 mg/mL), 30 mL Single-dose vial (NDC 0409-4279-16), packaged in 25 vials per tray (NDC 0409-4279-02), Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA.",87837,Class I,187221,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=187221
11303,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide USA,New York,New York,United States,2021-05-14,Presence of Particulate Matter: particulate matter identified as an insect in one vial.,"Sterile Water for Inj., USP, 25 x 100 mL Single Dose Vials per carton, Rx only, For Drug Diluent Use Only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, NDC Carton: 0409-4887-99; NDC Vial: 0409-4887-25",87831,Class II,187211,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=187211
15269,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,United States including Puerto Rico,New York,New York,United States,2020-08-04,Lack of Assurance of Sterility; potential loose metal overseal crimp defects.,"Fentanyl Citrate Inj., USP 100 mcg Fentanyl/2 mL (50 mcg/mL) 2 mL Single-dose Fliptop Vials, Rx only, Distributed by Hospira, Inc. Lake Forest, IL 60045 USA  NDC 0409-9094-12",86074,Class II,182608,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=182608
15904,2416101.0,Pfizer Inc.,Drugs,Class III,Ongoing,Nationwide within the United States,New York,New York,United States,2020-06-24,Failed Dissolution Specifications,"Duavee (conjugated estrogens/bazedoxifene) tablets 0.45/20 mg, packaged in 2 blister cards containing 15 tablets each (30 tablets), Rx Only, Distributed by Wyeth Pharmaceuticals LLC A subsidiary of Pfizer In Philadelphia, PA 19101 Made in Ireland, NDC 00008-1123-12",85725,Class III,181642,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=181642
16001,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Distributed Nationwide in the US,New York,New York,United States,2020-06-12,Presence of Particulate Matter: particulate matter identified after reconstitution.,"Unasyn (ampicillin sodium/sulbacatam) for injection, 1.5 g* per vial, Rx Only, 10 vials/carton, Made in Italy Distributed by Roerig Division of Pfizer Inc. New York, NY 10017 vial NDC 0049-0013-81, carton NDC 0049-0013-83",85754,Class II,181691,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=181691
17704,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"Nationwide within the United States and Albania, Israel, Serbia, Macedonia, Afghanistan, Botswana/South Africa/Zimbabwe, India, Israel, Rwanda, Uruguay, Mongolia",New York,New York,United States,2020-03-05,Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.,"Elelyso (taliglucerase alfa) for injection, 200 units/vials,, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017.  NDC 0069-0106-01",85067,Class II,180008,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=180008
18189,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the USA.,New York,New York,United States,2020-02-13,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.","Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2180-30.



",84860,Class II,179551,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=179551
18190,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the USA.,New York,New York,United States,2020-02-13,"Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.","Caduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, Distributed by: Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, Made in Germany, NDC 0069-2160-30.",84860,Class II,179552,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=179552
18261,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the U.S. and Puerto Rico,New York,New York,United States,2020-02-10,"Defective Container: confirmed customer reports for vials with loose metal overseal crimp defects, which may result in lack of assurance of sterility.","Fentanyl Citrate Inj., USP 100 mcg Fentanyl/2 mL (50 mcg/mL), 2 mL Single-dose Vial, Each Tray contains 25 Vials, Intravenous or Intramuscular Use, Rx only, Distributed by Hospira, Inc. Lake Forest, IL 60045, NDC 00409-9094-12 (vial), 00409-9094-22 (tray).",84833,Class II,179516,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=179516
19682,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide within the United States including Puerto Rico.,New York,New York,United States,2019-12-06,Labeling: Incorrect  or Missing Lot and/or expiration date.,"25% Dextrose Injection, USP 2.5 grams (250 mg/mL) 10 mL Single-dose, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-1775-10",84366,Class II,178145,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=178145
21227,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the United States and Puerto Rico,New York,New York,United States,2019-10-09,Lack of Assurance of Sterility:  Bag has the potential to leak.,"10% LMD in 5% Dextrose Injection Dextran 40 in Dextrose Injection, USP,  500 mL bags, Rx only, Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7418-13",83947,Class II,176791,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=176791
21530,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide in the USA,New York,New York,United States,2019-10-01,Labeling: Incorrect or Missing Lot and/or Exp Date.  The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.,"ethosuximide capsules, USP, 250 mg, 100-count bottle, Rx Only, Distributed by: Greenstone LLC Peapack, NJ 07977 Made in Netherlands. NDC 59762-2250-2",83788,Class III,176356,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=176356
21531,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide in the USA,New York,New York,United States,2019-10-01,Labeling: Incorrect or Missing Lot and/or Exp Date.  The expiry date on the product label is incorrect. The label states an expiry date of 09/2021 when it should be 09/2020.,"Zarontin (ethosuximide capsules, USP) 250 mg, 100-count bottle, Rx Onl,y Made in Netherlands Distributed by Parke-Davis Division of Pfizer In NY, NY 10017, NDC 0071-0237-24",83788,Class III,176357,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=176357
21969,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide US and Puerto Rico,New York,New York,United States,2019-09-12,Lack of Assurance of Sterility,"Bacteriostatic Water for Injection, USP, 30 mL vials, Rx only, Mfd. for: Hospira, Inc., Lake Forest, IL 60045 USA.  NDC Vial:  0409-3977-01; NDC Carton: 0409-3977-03",83699,Class II,176171,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=176171
22159,2416101.0,Pfizer Inc.,Drugs,Class II,Completed,Nationwide in the USA and Puerto Rico.,New York,New York,United States,2019-08-28,Microbial Contamination of Non-Sterile Products: contamination with Burkholderia and Pseudomonas.,"RELPAX (eletriptan HBr) tablets, 40 mg, packaged in a) 6-count (1 card x 6 tablets) per carton, NDC 0049-2340-45; b) 12-count (2 cards x 6 tablets) per carton, NDC 0049-2340-05, Rx only, Made in Ireland, Distributed by Pfizer Roerig, Division of Pfizer Inc., NY, NY  10017.",83533,Class II,175634,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=175634
23628,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"United States, PR, and Guam",New York,New York,United States,2019-07-12,Lack of Assurance of Sterility: Bags have the potential to leak.,"Milrinone Lactate Injection 200 mcg (0.2 mg)/mL* in 5% Dextrose Injection 40 mg/200 mL, 200 mL bag, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-2776-02, Barcode (01)00304092776028.",83267,Class II,174495,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=174495
23629,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"United States, PR, and Guam",New York,New York,United States,2019-07-12,Lack of Assurance of Sterility: Bags have the potential to leak.,"Milrinone Lactate Injection 200 mcg (0.2 mg)/mL* in 5% Dextrose Injection, 20 mg/100 mL, 100 mL bag, Rx Only, Hospira, Inc., Lake Forest, IL 60045 USA,  NDC 0409-2776-23, Barcode (01)00304092776233.",83267,Class II,174496,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=174496
24967,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide in the USA,New York,New York,United States,2019-05-13,"Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg eletriptan, instead of 40mg, on one side of the carton.","Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per blister pack, NDC 0049-2340-05; b) 6 tablets 1 card x six 40 mg tablets per blister pack, NDC 0049-2340-45, Rx Only, Made in Ireland, Distributed by Roerig, Division of Pfizer Inc, NY NY 10017.


",82715,Class III,172496,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=172496
25617,2416101.0,Pfizer Inc.,Drugs,Class I,Terminated,United States and Puerto Rico,New York,New York,United States,2019-03-29,Presence of Particulate Matter; glass particulates,"8.4% Sodium Bicarbonate Injection, USP 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL) 50 mL Single-dose fliptop vial, 25 vials per carton, Rx only Hospira, Inc. Lake Forest, IL 60045 USA ---- NDC 0409-6625-02",82362,Class I,171445,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171445
25637,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Cleocin Phosphate (clindamycin injection), USP, 300 mg/ 2 mL (150 mg/mL), 2 mL-vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017, NDC 0009-6582-02",82386,Class III,171515,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171515
25638,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Cleocin Phosphate, clindamycin injection, USP, 600 mg/ 4 mL (150 mg/mL), 4 mL vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017, NDC 0009-3124-01",82386,Class III,171644,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171644
25639,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Cleocin Phosphate, clindamycin injection, USP, 900 mg/ 6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by Pharmacia & Upjohn Co, Division of Pfizer, Inc, New York, NY 10017. NDC 0009-3447-01",82386,Class III,171645,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171645
25640,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Clindamycin Injection, USP, 300 mg/ 2 mL (150 mg/mL), 2 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA.,NDC 47781-619-94",82386,Class III,171646,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171646
25641,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Clindamycin Injection, USP, 600 mg/ 4 mL (150 mg/mL), 4 mL vials, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC 47781-620-94",82386,Class III,171647,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171647
25642,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA and Guam,New York,New York,United States,2019-03-29,Failed Impurities/Degradation Specifications: High out-of-specification (OOS) results were demonstrated for several specified impurities at the 24-month time point,"Clindamycin Injection, USP, 900 mg/6 mL (150 mg/mL), 6 mL vial, Rx only, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA. NDC 47781-621-94",82386,Class III,171648,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=171648
27589,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide within the United States,New York,New York,United States,2018-12-18,Superpotent Drug.,"Levoxyl (levothyroxine sodium tablets, USP) tablets 112 mcg, 100-count bottle,  Rx Only,Distributed by Pfizer Inc. New York, NY 10017, NDC 60793-855-01",81731,Class II,169646,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=169646
27776,2416101.0,Pfizer Inc.,Devices,Class II,Completed,US Nationwide Distribution and PR,New York,New York,United States,2018-12-04,The firm received complaints of the wrap coming apart and leaking granular material,"Thermacare Muscle Pain Therapy HeatWraps:
a) UPC 0573301314
b) UPC 0573301303

Product Usage:
Provides heat therapy for temporary relief of minor muscular and joint aches and pains associated with overexertion, sprains, and arthritis.
",81178,Class II,167682,CDRH,https://www.accessdata.fda.gov/scripts/ires/?Product=167682
27777,2416101.0,Pfizer Inc.,Devices,Class II,Completed,US Nationwide Distribution and PR,New York,New York,United States,2018-12-04,The firm received complaints of the wrap coming apart and leaking granular material,"Thermacare HeatWraps Menstrual
a) UPC 0573302002
b) UPC 0573302044

Product Usage:
Provides heat therapy for temporary relief of minor menstrual cramp pain and associated back aches.
",81178,Class II,167683,CDRH,https://www.accessdata.fda.gov/scripts/ires/?Product=167683
27778,2416101.0,Pfizer Inc.,Devices,Class II,Completed,US Nationwide Distribution and PR,New York,New York,United States,2018-12-04,The firm received complaints of the wrap coming apart and leaking granular material,"Thermacare HEATWRAPS JOINT PAIN THERAPY, 8 HEATWRAPS; MUSCLE PAIN THERAPY, 3 HEATWRAPS
a) UPC 0573301311
b) UPC 0573301311 

Product Usage:
Provides heat therapy for temporary relief of minor muscular and joint aches and pains associated with overexertion, sprains, and arthritis.
",81178,Class II,167684,CDRH,https://www.accessdata.fda.gov/scripts/ires/?Product=167684
28902,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the US and Puerto Rico,New York,New York,United States,2018-10-24,Lack of assurance of sterility: loss of container integrity.,"Meropenem for Injection, USA (I.V.), 1 gram/vial, 25 vials per carton, Sterile, Rx Only, Manufactured for: Hospira, Inc., Lake Forest, IL 60045, USA.  NDC carton: 0409-3506-01; NDC vial: 0409-3506-11",81311,Class II,168187,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=168187
29181,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the USA and Puerto Rico,New York,New York,United States,2018-10-11,"Correct Labeled Product Mispack: confirmed report involving a single unit of properly labeled Heparin in 0.45% Sodium Chloride for Injection (NDC 0409-7651-03, Lot 87903FW) that was found inside a case of Magnesium Sulfate in Water for Injection.","Magnesium Sulfate in Water for Injection (0.325 mEq Mg++/mL) 40 mg/mL, 20 g Total, 500 mL Single-Dose Container bag, Rx only, Hospira, Inc. Lake Forest, IL 60045 USA, NDC 0409-6729-03.",81126,Class II,167488,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=167488
29202,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide,New York,New York,United States,2018-10-09,CGMP Deviations; rejected product was used to manufacture final bulk lot,"Glipizide XL (glipizide) extended-release tablets 5 mg 500-tablet bottle, Rx only Distributed by: Greenstone LLC. Peapack, NJ 07977 --- NDC 59762-0541-2",81028,Class II,167260,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=167260
29316,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"U.S.A. nationwide.
The following countries received product from Lot S91616: Albania, South Africa, Israel, Afghanistan, Rwanda, Botswana, Zimbabwe and Iraq as part of the Compassionate Use Program.",New York,New York,United States,2018-10-02,Lack of assurance of sterility -Reports of loose metal ferrule crimps on vials for injection.  The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.,"Elelyso (taliglucerase alfa) for injection, 200 units/vial, single-use vial, Rx only, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, NDC  0069-0106-01",81050,Class II,167354,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=167354
29909,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide USA,New York,New York,United States,2018-09-07,Failed Impurities/Degradation Specifications; Out of specification stability testing results at the 18 month time point,"Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 2.5 mL Single-use Vial, Rx only, Sterile, Manufactured for: Hospira, Inc, Lake Forest, IL 60045 USA.  NDC:  0409-1140-01",80923,Class III,166973,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=166973
30002,3009635616.0,Pfizer Global Supply,Drugs,Class II,Terminated,Nationwide within the United States,Andover,Massachusetts,United States,2018-08-30,Labeling Error: Not elsewhere classified. product has a dosage cup  marked in teaspoons and the instructions on the label are described in milliliters.,"Children s Advil Suspension Ibuprofen Oral Suspension, 100 mg per 5mL, 4 FL OZ (120 ml) bottle, Pfizer, Madison, NJ 07940 USA, NDC 0573-0207-30, UPC 3-0573-0207-30-0",80876,Class II,166784,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=166784
33990,2416101.0,Pfizer Inc.,Drugs,Class I,Terminated,Nationwide in the USA,New York,New York,United States,2018-03-14,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation. Mfd For: Teva Parenteral Medicines, Inc., Irvine, CA 92618. NDC: 0703-0110-01",79114,Class I,161394,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=161394
33991,2416101.0,Pfizer Inc.,Drugs,Class I,Terminated,Nationwide in the USA,New York,New York,United States,2018-03-14,Non-Sterility: Confirmed customer complaints of glass product container vials that may be empty or cracked.,"Hydromorphone, Hydrochloride, Injection, USP CII, 10 mg/mL, Rx Only, 1 mL Single-dose Vial, High Potency Formulation.  Hospira, Inc., Lake forest, IL 60045 USA.  NDC:  0409-2634-01",79114,Class I,161947,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=161947
34348,1925262.0,Hospira Inc. A Pfizer Company,Drugs,Class II,Terminated,Nationwide in the USA and Puerto Rico.,Mcpherson,Kansas,United States,2018-03-02,"Defective Container: Cracked glass at the rim surface of glass vials, covered by the stopper and crimp seal.","Labetalol Hydrochloride Injection, USP, 100 mg/ 20 mL (5 mg/mL), 20 mL Multidose Vial, Rx only, labeled as a) Hospira, Inc., Lake Forest, IL 60045, NDC 0409-2267-20; and b) NOVAPLUS, Manufactured by Hospira, Inc., Lake Forest, IL  60045, NDC 0409-2267-25.",79238,Class II,161730,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=161730
35669,3002807097.0,Pfizer Manufacturing Deutschland GmbH,Drugs,Class II,Terminated,Germany; products were packaged at the Pfizer Manufacturing Deutshland Gmbh location and then distributed to other countries.  No product distributed in the United States or its territories.,Freiburg im Breisgau,-,Germany,2018-01-08,Microbial Contamination of Non-Sterile Products,"FOR EXPORT ONLY Atorvastatin calcium Film-Coated Tablets a) 80 mg SMT Tabs Bulk, b) 40 mg SMT G EP PR KR, c) 20 mg SMT G EP PR, d) 20 mg SMT G EP PR KR, FOR MANUFACTURING, PROCESSING OR REPACKAGING",78682,Class II,160108,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=160108
35754,2416101.0,Pfizer Inc.,Drugs,Class I,Terminated,Nationwide in the USA,New York,New York,United States,2018-01-04,SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent,"diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg,  a) 100-count bottle (NDC 59762-1061-1), b) 1000-count bottle (NDC 59762-1061-2), Rx Only, Distributed by: Greenstone LLC. Peapack, NJ 07977",78332,Class I,159218,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=159218
35760,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the USA,New York,New York,United States,2018-01-04,SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent,"Zoloft (sertraline HCl) tablets 25 mg* 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., NY, NY, 10017 NDC 0049-4960-30",78332,Class I,159220,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=159220
35883,2416101.0,Pfizer Inc.,Drugs,Class I,Terminated,Nationwide USA and Puerto Rico,New York,New York,United States,2017-12-20,Presence of Particulate Matter: glass particulate found in vial,"Vancomycin Hydrochloride for Injection, USP. 750 mg.  Sterile Powder. Rx Only. Hospira, Inc., Lake Forest, IL 60045 USA.  NDC:  0409-6531-02",78000,Class I,158471,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158471
36979,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2017-10-03,CGMP Deviations: Firm failed to control impurity for color change at the API stage.,"Deferoxamine Mesylate for injection, USP, Single-use Vial, 500 mg/vial, 10 mL vial. Intravenous, Intramuscular, Subcutaneous Use, Rx Only, Hospira, Inc., Lake Forest IL USA, NDC 0406-2336-10.",77731,Class III,157779,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=157779
37143,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide in the USA,New York,New York,United States,2017-09-22,"Non-Sterility: cracked or chipped glass at the neck of Sterile Water for Injection vials.  
","Sterile Water for Injection, USP Single Dose 100 mL vials, Rx only, Manufactured by Hospira, Inc., Lake Forest, IL 60045 USA for Genentech, Inc., South San Francisco, CA 94080-4990. NDC 50242-901-24",78048,Class II,158558,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158558
37205,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,United States Nationwide (including Puerto Rico) and Singapore,New York,New York,United States,2017-09-15,Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.,"HYDROmorphone HCl Injection, USP, 2 mg/mL, 1mL Single-use vial, packaged in cartons of 25 vials, Rx only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-3365-11 (carton) and 0409-3365-01(vial)",77956,Class II,158326,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158326
37206,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,United States Nationwide (including Puerto Rico) and Singapore,New York,New York,United States,2017-09-15,Lack of sterility assurance: resulting from use of a damaged sterilizing filter for nitrogen used in the manufacturing process.,"Levophed (norepinephrine bitartrate) injection, USP, 4 mg/4 mL (1mg/mL), 4mL Fill in 5 mL Single dose Fliptop Vial, Rx only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-3375-04",77956,Class II,158328,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158328
37242,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2017-09-15,Failed Dissolution Specifications,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 600 mg/120 mL total volume (When constituted with 105 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-20.
",77862,Class III,158089,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158089
37243,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2017-09-15,Failed Dissolution Specifications,"Quillivant XR methylphenidate HCl, for extended-release oral suspension, 750mg/150 mL total volume (When constituted with 131 mL of water, 25 mg/5 mL (5 mg/mL) when reconstituted,   Rx Only, Distributed by Nextwave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc., New York, NY 10017, Manufactured by Tris Pharma, Inc., Monmouth Junction, NJ 08852, NDC 24478-200-25.
",77862,Class III,158712,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=158712
38550,1021343.0,Hospira a Pfizer Company,Drugs,Class II,Terminated,"U.S. (including Puerto Rico), Dutch Antilles, Barbados, Canada, Philippines, Kuwait, and Singapore",Rocky Mount,North Carolina,United States,2017-08-01,Lack of Sterility Assurance,"Potassium Phosphates Inj., USP, 45 mM (3 mM P/mL) Also contains: 66 mEq K+ (4.4 mEq/mL) 15 mL, Single-dose, Caution: Must Be Diluted, Rx Only, Mfd by Hospira, Inc. Lake Forest, IL 60045 USA, NDC: 0409-7295-01",77533,Class II,156309,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=156309
38551,1021343.0,Hospira a Pfizer Company,Drugs,Class II,Terminated,"U.S. (including Puerto Rico), Dutch Antilles, Barbados, Canada, Philippines, Kuwait, and Singapore",Rocky Mount,North Carolina,United States,2017-08-01,Lack of Sterility Assurance,"8.4% Sodium Bicarbonate Inj., USP 50 mL Single-dose, 50 mEq (1 mEq/mL) 4.2 grams (84 mg/mL), Rx Only,  Mfd by Hospira, INC, Lake Forest, IL 60045 USA,  NDC: 0409-6625-02",77533,Class II,156992,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=156992
38552,1021343.0,Hospira a Pfizer Company,Drugs,Class II,Terminated,"U.S. (including Puerto Rico), Dutch Antilles, Barbados, Canada, Philippines, Kuwait, and Singapore",Rocky Mount,North Carolina,United States,2017-08-01,Lack of Sterility Assurance,"Succinylcholine Chloride Injection, USP 200 mg (20 mg/mL) Quelicin Multiple-dose vial, 10 mL,  For I.V. or I.M. use.  a.) one vial (NDC: 0409-6629-02), b.) 25 vial carton (NDC: 0409-6629-25).",77533,Class II,156995,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=156995
38553,1021343.0,Hospira a Pfizer Company,Drugs,Class II,Terminated,"U.S. (including Puerto Rico), Dutch Antilles, Barbados, Canada, Philippines, Kuwait, and Singapore",Rocky Mount,North Carolina,United States,2017-08-01,Lack of Sterility Assurance,"Neut Sodium Bicarbonate 4% (2.4 mEq) Additive Solution 5 mL , a.) Single-dose vial (NDC 0409-6609-02), b.) 25 vial carton (NDC 0409-6609-25), Rx Only, Mfd by Hospira, INC, Lake Forest, IL 60045 USA",77533,Class II,156996,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=156996
40802,1950222.0,Meridian Medical Technologies a Pfizer Company,Drugs,Class I,Ongoing,"Nationwide and Puerto Rico, Argentina, Austria, Australia, Belgium, Chile, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Latvia, Lithuania, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Singapore, Slovakia, Slovenia, Sweden, Switzerland, Taiwan, Thailand,  United Kingdom.  There has been no U.S. government or military distribution.",Brentwood,Missouri,United States,2017-04-28,Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication,"EpiPen 2-Pak (Epinephrine) Auto-Injectors 0.3 mg, Rx only, Manufactured for Mylan Specialty L.P., Morgantown WV 26505 by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company; NDC 49502-500-02 ---- ALSO LABELED OUTSIDE THE US AS ---- Epipen Auto-Injector 0.3 mg -Bright Stock labeled for multiple countries- manufactured for Mylan by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company.",76789,Class I,154185,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=154185
40803,1950222.0,Meridian Medical Technologies a Pfizer Company,Drugs,Class I,Ongoing,"Nationwide and Puerto Rico, Argentina, Austria, Australia, Belgium, Chile, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Latvia, Lithuania, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Saudi Arabia, Singapore, Slovakia, Slovenia, Sweden, Switzerland, Taiwan, Thailand,  United Kingdom.  There has been no U.S. government or military distribution.",Brentwood,Missouri,United States,2017-04-28,Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication,"EpiPen Jr. 2-Pak (Epinephrine) Auto-Injectors 0.15 mg, Rx only, Manufactured for Mylan Specialty L.P., Morgantown WV 26505 by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company; NDC 49502-500-02 ---- ALSO LABELED OUTSIDE THE US AS:  Epipen Auto-Injector Jr. 0.15 mg -Bright Stock labeled for multiple countries- manufactured for Mylan by Meridian Medical Technologies, Inc., Columbia, MD 21046, a Pfizer company.",76789,Class I,154467,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=154467
41885,3004945409.0,Pfizer Inc,Drugs,Class III,Terminated,Nationwide within US,Peapack,New Jersey,United States,2017-03-22,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 300 mg/60 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017
Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-10).",76663,Class III,153770,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=153770
41886,3004945409.0,Pfizer Inc,Drugs,Class III,Terminated,Nationwide within US,Peapack,New Jersey,United States,2017-03-22,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 750 mg/150 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017
Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-205-25).",76663,Class III,154227,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=154227
41887,3004945409.0,Pfizer Inc,Drugs,Class III,Terminated,Nationwide within US,Peapack,New Jersey,United States,2017-03-22,Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.,"Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 900 mg/180 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017
Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-30).",76663,Class III,154228,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=154228
42208,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2017-03-10,Subpotent Drug: Out of Specification (OOS) for potency at the 6-month stability time point.,"PROTONIX I.V. (pantoprazole sodium) for Injection, Equivalent to 40 mg pantoprazole per vial, For I.V. infusion only, Rx Only, Distributed by Wyeth Pharmaceuticals Inc, A subsidiary of Pfizer Inc, Philadelphia, PA 19101, Under license from Takeda GmbH, D78467 Konstanz, Germany, MADE IN FRANCE; packaged in A) Pfizer Injectables, 1 vial per carton (NDC 0008-0923-51) in a) bundles of 10 unit cartons (NDC 0008-0923-55) and b) 25 x 40 mg Vials per carton (NDC 0008-0923-60); B) NOVAPLUS, 1 vial per carton (NDC 00008-0941-01) in 25 x 40 mg Vials per carton (NDC 0008-0941-03); and C) PREMIERPro Rx, 1 vial per carton (NDC 0008-4001-01) in a) bundles of 10 unit cartons (NDC 0008-4001-10) and b) 25 x 40 mg Vials per carton (NDC 0008-4001-25).",75871,Class III,151496,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=151496
43431,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2017-01-06,Failed Impurities/Degradations Specifications; Out of specification results for two known degradation products and total impurities at 18 months,"Cytotec (misoprostol) Tablets, 200 mcg, 100 Tablets blister pack (10X10), For in-institution use only, Rx only, Distributed by G.D. Searle, Division of Pfizer, Inc., NY, NY --- NDC 0025-1461-34",75321,Class III,150045,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=150045
44711,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide,New York,New York,United States,2016-11-23,Superpotent,"LEVOXYL(R) (levothyroxine sodium tablets, USP), 200 mcg, 100 count bottles, Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN 37620, NDC 60793-860-01",75691,Class II,151061,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=151061
46468,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2016-09-27,Labeling: Incorrect or Missing Lot and/or Exp Date: Bottles were incorrectly labeled with an expiry date of 11/17; the correct date is 09/17.,"PREMARIN (conjugated estrogen tablets, USP) 1.25 mg, 1000- count bottle, Rx only, Distributed by: Wyeth Pharmaceuticals Inc. A subsidiary of Pfizer Inc. Philadelphia, PA 19101, NDC 0046-1104-91",75225,Class III,149711,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=149711
49673,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2016-05-20,Failed Tablet/Capsule Specifications: thick tablets exceeding specifications were found.,"Zoloft (sertraline HCl) tablets, 100 mg*, 30 count bottles, Rx only, Distributed by Roerig, Division of Pfizer, Inc., NY NY 10017, NDC 0049-4910-30.",73913,Class II,145404,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=145404
50826,3004945409.0,Pfizer Inc,Drugs,Class III,Terminated,Nationwide,Peapack,New Jersey,United States,2016-03-31,Labeling: Label Mix-Up,"Adult Robitussin PEAK COLD Cough & Chest Congestion DM Liquid 8 oz. Bottle (237 mL), Distributed by Pfizer, Madison, NJ 07940, NDC 0031-8736-18",73285,Class III,143756,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=143756
52102,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2016-02-01,FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.,"Lyrica (pregabalin) capsules, 50 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1013-68",73043,Class II,142882,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=142882
52103,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2016-02-01,FAILED TABLET/CAPSULE SPECIFICATIONS: Firm is recalling specific lots of pregabalin capsules due to the potential presence of deformed or damaged capsules.,"Lyrica (pregabalin) capsules, 75 mg, 90-count bottle, Rx only, Distributed by: Parke-Davis, Division of Pfizer Inc., NY, NY 10017, NDC 0071-1014-68",73043,Class II,142885,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=142885
53016,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2015-12-10,"Failed Dissolution Specification
","Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.
",72716,Class III,142023,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=142023
53887,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,Nationwide,New York,New York,United States,2015-10-29,Subpotent Drug,"Xanax (alprazolam) tablets, 0.25 mg, 100-count bottle, Rx only, Distributed by Pharmacia & Upjohn Co. Division of Pfizer Inc, NY, NY 10017, NDC 0009-0029-01",72199,Class II,140163,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=140163
59955,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2015-03-05,"Failed Impurities/Degradation Specifications 
","Oxecta(TM) (oxycodone HCl) tablets, 5 mg, 100 count bottles, Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc. Bristol, TN, NDC 60793-525-01",70614,Class III,134157,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=134157
59956,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2015-03-05,"Failed Impurities/Degradation Specifications 
","Oxecta(TM) (oxycodone HCl) tablets, 7.5 mg, 100 count bottles, Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc. Bristol, TN, NDC 60793-526-01",70614,Class III,134158,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=134158
61689,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"Pfizer shipped the affected product to 4,447 direct accounts. 

No federal government accounts received the affected product directly from Pfizer Inc.",New York,New York,United States,2014-12-09,Failed Tablet/Capsule Specifications: Product being recalled due to the potential presence of cracked or broken capsules.,"Tikosyn (dofetilide) 125 mcg (0.125 mg), a) 14-count bottle (NDC 0069-5800-61), b) 60-count bottle (NDC 0069-5800-60), Rx Only, Manufactured by Pfizer Labs, Division of Pfizer, Inc., NY, NY 10017.
",69724,Class II,131429,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=131429
62538,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2014-11-04,Crystallization: Impurities in a raw material used to manufacture the diluent can cause the formation of crystals in the diluent vials after cold storage. The TORISEL vials are not affected by this issue.,"TORISEL Kit (temsirolimus) injection, 25 mg/mL, 1 vial of TORISEL 25 mg/mL and 1 vial of 2.2 mL DILUENT per carton, Rx only, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA 19101; Diluent  MADE IN ITALY; NDC 0008-1179-01.",69479,Class III,130746,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=130746
64697,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2014-08-12,Failed pH Specification: A pH result of 2.9 was obtained at the 9 month stability test interval at 25C/60%RH. The registered specification for pH is 3.0 - 7.0,"Depo-Medrol (methylprednisolone acetate injectable suspension USP), 40 mg/ mL, 1 mL Single-Dose Vial, Rx only, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017  NDC 0009-3073-03  
DEPO-MEDROL methylprednisolone acetate Injectable Suspension USP, 40 mg per mL,  1 mL Single-Dose Vial, Rx ONLY, Distributed by Pharmacia & Upjohn Co Division of Pfizer Inc, New York NY 10017, NOVAPLUS is a registered trademark of Novation, LLC NDC 0009-3073-23",68876,Class III,128916,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=128916
64932,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,"Nationwide (Continental USA and Puerto Rico).  A portion of the bulk lot was supplied to Pfizer Germany for packaging into blisters for non- USA market.  One of these lots in Germany was placed in stability having acceptable results, therefore are not part of the recall scope.  Only the product distributed within US/PR market (bottles) is in the scope of this recall.",New York,New York,United States,2014-07-28,Failed Impurities/Degradation Specifications: Product from this lot may not meet specifications for a product degradant.,"Cardura XL (doxazosin mesylate extended release tablets, 4 mg, 30-count bottle, Rx only, Distributed by Roerig Division of Pfizer Inc., New York, NY 10017,  NDC 0049-2710-30",68639,Class III,128387,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=128387
65092,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2014-07-17,Labeling: Incorrect or missing lot and or Exp Date: The bottles were labeled with an incorrect expiry date 11/2016.  The correct expiry date is 09/2016.,"VIRACEPT (R) (nelfinavir mesylate) Tablets, 625 mg, 120-count bottle, Rx only, Manufactured by: Agouron Pharmaceuticals, Inc. A Pfizer Company,  Distributed by: ViV Healthcare Company, Research Triangle Park, NC 27709  NDC 63010-027-70",68660,Class III,128403,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=128403
65997,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,"Nationwide, Italy and Republic of South Korea",New York,New York,United States,2014-05-30,Defective Container: Tamper evident ring failures discovered on some bottles.,"GREENSTONE BRAND fluconazole for Oral Suspension, ORANGE FLAVORED, 40 mg/mL, when reconstituted, Rx only, Distributed by Greenstone LLC Peapack, NJ 07977.  MADE IN INDIA.  NDC 59762-5030-1",67532,Class II,125687,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=125687
66440,2416101.0,Pfizer Inc.,Drugs,Class II,Terminated,US Nationwide including Puerto Rico and US Virgin Islands. 65 federal government accounts received the affected product directly from Pfizer Inc,-,-,-,2014-04-22,Presence of Foriegn Tablets/Capsules: A single Tikosyn (dofetilide) 250 mcg capsule was discovered in one bottle of Tikosyn (dofetilide) 500 mcg (0.5 mg).,"Tikosyn  (dofetilide) 500 mcg (0.5mg) capsules, 60-count bottle, Rx only Pfizer Labs, Division of Pfizer Inc. NY, NY 10017, NDC 00069-5820-60",67870,Class II,126537,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=126537
67876,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,US nationwide (including PR),New York,New York,United States,2014-02-03,Failed Dissolution Specification; 8 hr stability timepoint,"Glucotrol XL (glipizide) extended release tablets, 5 mg, 100 count bottles, Rx only, Distributed by Roerig, Division of Pfizer Inc, NY, NY --- NDC 0049-1550-66",66816,Class III,123533,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=123533
68690,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2014-01-16,Failed Impurities/Degradation Specifications: Pfizer is recalling certain lots due to out of specification results for azithromycin N-oxide degradant.,"Zithromax (azithromycin for injection), 500 mg/vial, Sterile, Rx Only, For I.V. infusion only, No latex, No preservative, Made in Ireland, Distributed by Pfizer Labs, Division of Pfizer Inc, NY, NY 10017, NDC 0069-3150-84

",67137,Class III,124761,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=124761
73889,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2013-06-28,Failed Dissolution Specifications: Pfizer Inc. is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product  may not meet the dissolution specification for conjugated estrogens.,"Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/2.5 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA, NDC 0046-0875-11",65393,Class III,118768,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118768
73890,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide and Puerto Rico,New York,New York,United States,2013-06-28,Failed Dissolution Specifications: Pfizer Inc. (Pfizer) is recalling PREMPRO (conjugated estrogens/medroxyprogesterone acetate tablets) because certain lots for this product  may not meet the specification for conjugated estrogens dissolution.,"Prempro (Conjugated Estrogen/Medroxyprogesterone Acetate) tablets 0.625 mg/5.0 mg, 1 blister card containing 28 tablets, Rx only, Wyeth Pharmaceuticals Inc., Philadelphia, PA 1910, NDC 0046-0975-11

",65393,Class III,118769,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118769
74043,3004945409.0,Pfizer Inc,Drugs,Class III,Terminated,Nationwide and Puerto Rico,Peapack,New Jersey,United States,2013-06-19,Failed Dissolution Specification,"Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.",65324,Class III,118558,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118558
74818,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles (NDC 60793-850-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118097,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118097
74819,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles (NDC 60793-851-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118098,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118098
74820,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles (NDC 60793-852-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118099,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118099
74821,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles (NDC 60793-853-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118101,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118101
74822,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count bottles (NDC 60793-854-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118102,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118102
74823,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count bottles (NDC 60793-855-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118103,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118103
74824,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 125 mcg, packaged in a) 100-count bottles (NDC 60793-856-01) and b) 1000-count bottles (NDC 60793-856-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118104,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118104
74825,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-count bottles (NDC 60793-857-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118105,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118105
74826,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles (NDC 60793-858-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118106,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118106
74827,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 175 mcg, packaged in a) 100-count bottles (NDC 60793-859-01) and b) 1000-count bottles (NDC 60793-859-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118107,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118107
74828,1000208638.0,"King Legacy, a wholly owned subsidiary of Pfizer",Drugs,Class II,Terminated,Nationwide and Puerto Rico,Bristol,Tennessee,United States,2013-05-20,Subpotent Drug: The products were below specification for potency at the expiry stability point.,"Levoxyl (levothyroxine sodium) tablets, USP, 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles (NDC 60793-860-10), Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620",65172,Class II,118108,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=118108
75590,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened..,"Levoxyl (levothyroxine sodium) tablets, USP 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles ( NDC 60793-850-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117148,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117148
75591,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles ( NDC 60793-851-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117149,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117149
75592,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 75 mcg,  packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117150,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117150
75593,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened..,"Levoxyl (levothyroxine sodium) tablets, USP 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles ( NDC 60793-853-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117151,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117151
75594,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened..,"Levoxyl (levothyroxine sodium) tablets, USP 100 mcg, packaged in a) 100-count bottles (NDC 60793-854-01) and b) 1000-count bottles ( NDC 60793-854-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117152,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117152
75595,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 112 mcg, packaged in a) 100-count bottles (NDC 60793-855-01) and b) 1000-count bottles ( NDC 60793-855-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117153,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117153
75596,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened,"Levoxyl (levothyroxine sodium) tablets, USP 125 mcg, packaged in a)  100-count bottles (NDC 60793-856-01) and b) 1000-count bottles ( NDC 60793-856-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117154,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117154
75597,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 137 mcg, packaged in a) 100-count bottles (NDC 60793-857-01) and b) 1000-count bottles ( NDC 60793-857-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117155,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117155
75598,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 150 mcg, packaged in a) 100-count bottles (NDC 60793-858-01) and b) 1000-count bottles ( NDC 60793-858-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117156,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117156
75599,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 175 mcg, packaged in a) 100-count bottles (NDC 60793-859-01) and b) 1000-count bottles ( NDC 60793-859-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117157,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117157
75600,2416101.0,Pfizer Inc.,Drugs,Class II,Ongoing,Nationwide and PR,New York,New York,United States,2013-04-18,Chemical contamination: emission of strong odor after package was opened.,"Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles ( NDC 60793-860-10 ) Rx only, Manufactured and Distributed by:  King Pharmaceuticals, Inc., Bristol, TN  37620.",64835,Class II,117158,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=117158
76081,2416101.0,Pfizer Inc.,Drugs,Class III,Terminated,Nationwide,New York,New York,United States,2013-03-26,Lack of Assurance of Sterility; potential that a low level of endotoxins may be present in the diluent vials.,"TORISEL Kit (temsirolimus) injection, 25 mg/mL, CONCENTRATED, Rx Only,  Packaged in a carton containing 1 vial TORISEL injection and 1 vial DILUENT for TORISEL, Distributed by Wyeth Pharmaceuticals Inc., A subsidiary of Pfizer Inc., Philadelphia, PA --- NDC 0008-1179-01",64690,Class III,116774,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=116774
83126,1950222.0,"Meridian Medical Technologies, Inc. dba Meridian Medical Technologies, Inc. a Pfizer Company",Drugs,Class II,Terminated,"Nationwide, military, Italy, Singapore, Sweden, and Canada.",Saint Louis,Missouri,United States,2012-06-11,"Impurities/Degradation Products: High Out of Specification levels for carbostyril, a known degradation product of diazepam.","Diazepam Injection, USP, 10 mg Automatic, Autoinjector for Buddy Use, 5 mg/mL, 2 mL autoinjector, 15-count autoinjectors per carton, Rx only, Meridian Medical Technologies, Columbia, MD  21046; A subsidiary of King Pharmaceuticals, Inc.; NSN 6505-01-274-0951, NDC 11704-600-01.",62015,Class II,109700,CDER,https://www.accessdata.fda.gov/scripts/ires/?Product=109700
